CALM Psychotherapy in Patients With Metastatic Cancer in Chile
ConditionMetastatic Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFundacion Arturo Lopez Perez
About this trial
Patients with metastatic cancer experience multidimensional challenges that increase the risk of emotional distress, which must be addressed by the health team. Chile lacks evidence on effective therapeutic interventions in this population. CALM is a brief, individual (with the presence of a caregiver in one or more sessions) and evidence-based psychotherapy developed at The Princess Margaret Cancer Center. It consists of an intervention of 3 to 6 psychotherapy sessions over a period of 3 to 6 months. The Global CALM program aims to expand CALM research around the world, a program to which FALP has subscribed. Objective: To evaluate the preliminary efficacy of CALM in a sample of patients with metastatic cancer in Chile.
Phase 2 study of preliminary, pseudo-experimental efficacy, without a control group. The study will be carried out in Falp and Corporación Valientes.
Eligibility criteria
Qualifiers
be ≥18 years of age;
be fluent in Spanish;
be able to give informed consent; and
have received a diagnosis of advanced or metastatic solid tumor cancer with a reduced life expectancy but greater than six months.
Disqualifiers
significant verbal communication difficulties;
cognitive impairment indicated by the clinical team or in the patient's file.
Patients currently in psychotherapy.
Active suicidal ideation
Trial design
Treatments tested in this trial
- CALM psychotherapy
Treatment groups
34 Participants
are divided into 1 treatment groupSponsors and collaborators
Fundacion Arturo Lopez Perez
Lead sponsor
University of Toronto
Collaborator
Source ClinicalTrials.gov